A Supercharged Fibre That Mimics Ozempic Just Got Approved for EU Foods

After 12 years of regulatory effort, a fibre ingredient designed to nudge the body into releasing its own appetite-suppressing hormones has cleared one of the world's most rigorous food safety reviews. Inulin-propionate ester, or IPE, received European Commission authorization on June 9, 2026, opening the door for its use in cereal bars and fruit smoothies across the EU. The researchers behind it say it is not a drug, but a preventive nutrition tool that borrows a trick from pharmacology: getting the gut to produce more of the hormones that weight-loss medications like Ozempic are designed to mimic.

IPE Boosts GLP-1 and PYY Hormones at Just 10 Grams Per Day

The appeal of IPE starts with a basic problem of gut biology. Dietary fibre is fermented by bacteria in the large intestine, producing short-chain fatty acids (SCFAs). When SCFA levels are high enough, the gut releases GLP-1 and PYY, two hormones that signal fullness to the brain, slow gastric emptying, and suppress appetite. The catch is volume: typical dietary fibre requires roughly 80 grams daily to push SCFA concentrations high enough to have a meaningful hormonal effect. The recommended daily intake for most adults is 25-30 grams, and most people fall short of even that.

IPE sidesteps the volume problem by delivering propionate, one of the key SCFAs, directly to the large intestine. The molecule works by chemically attaching propionate to inulin, a carbohydrate found naturally in many plants. The resulting compound passes through the stomach and small intestine undigested, then is cleaved apart by gut bacteria in the large intestine, releasing a concentrated dose of propionate exactly where it needs to act. As Douglas Morrison, one of the researchers who created IPE, put it: the propionate is "supercharging a dose of fibre."

In clinical trials, just 10 grams of IPE per day raised blood levels of GLP-1 and PYY, and participants reported eating less. The hormone targets are the same ones that GLP-1 receptor agonists like semaglutide act on, though through a fundamentally different mechanism: IPE stimulates the body's own production rather than supplying a synthetic analogue.

Weight Gain Prevention in Middle-Aged Adults, Body Composition Shifts in Younger Groups

Two randomised-controlled trials form the core evidence base. In the first, 60 overweight people aged 40 to 65 took a daily 10-gram dose of IPE for six months. None of the IPE group gained significant weight, compared to 17 percent of the control group. Gary Frost, the other researcher leading the project, described the finding directly: "We showed in a randomised-controlled trial in middle-aged people that when it's consumed daily, it prevents weight gain."

A second trial followed 270 overweight adults aged 20 to 40 for a year. Body weight did not shift significantly in this group, but body composition did: IPE users gained on average more than a kilogram of fat-free mass. Frost noted the distinction: "In young people, although you don't see the impact on body weight, you see a change in body composition. These young people ended up with a higher lean body mass."

The European Food Safety Authority reviewed this body of evidence and concluded IPE is safe to eat under the proposed conditions of use, a process that took Frost, Morrison, and their team 12 years to complete.

How IPE Bypasses the Small Intestine to Reach Its Target

The design challenge that drove IPE's creation was essentially a delivery problem. Propionate is produced naturally during fibre fermentation, but generating enough of it through diet alone would require quantities of fibre that are impractical to consume. Inserting a tube to deliver propionate directly, as Morrison noted, is "not particularly pleasant" from either end.

Attaching propionate to inulin solved the delivery problem by exploiting the gut's own architecture. Inulin is not broken down by human digestive enzymes, so the IPE molecule rides through the upper digestive tract intact. When it reaches the large intestine, the microbial population there cleaves the ester bond between propionate and inulin, releasing the SCFA in situ. The approach is conceptually similar to ongoing research examining how fiber-based dietary strategies can complement GLP-1 therapies, though IPE predates and operates independently of drug treatment.

EU authorization permits IPE in cereal bars at up to 17 grams per 100 grams of product, and in fruit smoothies at up to 3 grams per 100 millilitres. Products must be labelled as containing 'inulin-propionate ester'. Imperial College Hammersmith Campus, where the research originated, holds five years of exclusive market protection in the EU, running until June 30, 2031.

Limitations: Mixed Evidence and Questions About Muscle Versus Mass

Not everyone is convinced the evidence is fully settled. Brendan Gabriel at the University of Aberdeen has noted that the case for IPE's benefits is mixed, and the trials showing weight gain prevention in adults over 40 involved small participant numbers, with just 60 people in the six-month study.

The body composition finding in younger adults carries its own caveat: the method used to measure fat-free mass did not distinguish between muscle specifically and other non-fat tissue. Whether the observed lean mass gain reflects true muscle accretion or some combination of other tissue types remains unclear. A recent review of fiber and GLP-1 receptor agonist research has similarly flagged that optimal fibre types, doses, and timing in this space still lack clinical consensus.

The only reported side effect in trials was increased flatulence, a predictable consequence of delivering high concentrations of fermentable substrate to the large intestine and consistent with what most high-fibre diets produce. A small proportion of users may also detect a faint bitter taste, though most cannot.

EU Launch Expected Within 12 Months, GLP-1 Drug Synergy Under Study

Frost and Morrison are in active discussions with food companies about product launches, with smoothies, cereals, and breads all under consideration. The European Commission's authorization took effect June 30, 2026, and the researchers expect IPE-containing products to reach EU shelves within 12 months.

UK regulatory approval has not yet been granted but is anticipated. The question of how IPE might interact with GLP-1 drug therapy is also on the research agenda: future studies are planned to investigate whether IPE can help preserve lean mass in people using GLP-1 medications, and whether it might blunt weight regain after those drugs are stopped. Given that fiber supplementation has been proposed as a complementary strategy for patients who discontinue GLP-1 receptor agonist therapy, IPE's mechanism makes it a plausible candidate for that role, though the trials to confirm it have not yet been done.

For now, IPE is framed as a preventive nutrition tool, something to add to an ordinary diet rather than a treatment to prescribe. Whether a fibre in a smoothie can move the needle on population-level weight gain remains to be seen at scale, but the regulatory path that most food ingredients never complete is now behind it.

Evidence rating

EMERGING — 88/100

Caveats:

• The weight-gain prevention trial was small (n=60), limiting statistical power and generalisability.
• The larger trial (n=270) found no significant difference in body weight after one year; the observed increase in fat-free mass could not confirm whether the gain was muscle or other non-fat tissue.
• An independent researcher (Brendan Gabriel, University of Aberdeen) characterises the overall evidence as mixed.
• EU regulatory approval confirms safety, not efficacy; IPE is not approved as a medicine or weight-loss treatment.
• Funding sources for the underlying trials are not disclosed in this report.
• UK regulatory approval has not yet been granted; EU market availability is projected within 12 months.

Two randomised controlled trials underpin these findings: one in 60 overweight adults aged 40–65 (6 months) and one in 270 overweight adults aged 20–40 (12 months). The smaller trial showed a statistically notable difference in weight gain between groups, but its sample size limits confidence; the larger trial found no significant body-weight difference, with only a body-composition signal whose tissue type could not be confirmed. Results have not yet been independently replicated by separate research groups.

References

1. A type of fibre that stimulates GLP-1 release approved for use in food | New Scientist. https://www.newscientist.com/article/2532336-a-type-of-fibre-that-stimulates-glp-1-release-approved-for-use-in-food/
2. Glucagon-like peptide 1 (GLP-1) – PMC. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030647/
3. Tong Bu, Ziyan Sun, Yi Pan, Xia Deng, Guoyue Yuan (2024). Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism. Diabetes & Metabolism Journal. https://doi.org/10.4093/dmj.2023.0277
4. A Trial to Assess Gastrointestinal Responses to Dietary Fibers in Adults Using Weight Loss Medications | ClinicalTrials.gov. clinicaltrials.gov. https://clinicaltrials.gov/study/NCT07012317
5. Yuxin Wang, Jiaxin Liu, Kristin Verbeke, Naschla Gasaly Retamal, Renate Akkerman, Paul de Vos (2026). Dietary Fiber and Glucagon-Like Peptide-1 Receptor Agonists in Obesity Management: Converging Mechanisms, Interactions, and Strategies for Durable Weight Control. Advances in Nutrition. https://doi.org/10.1016/j.advnut.2026.100647
6. Brittany VB Johnson (2026). Fiber Supplementation during and after Glucagon-Like Peptide-1 Receptor Agonists Treatment: A Perspective on Clinical Benefits. The Journal of Nutrition. https://doi.org/10.1016/j.tjnut.2026.101436